Lifeboat Foundation

Elon Musk’s Neuralink is under federal investigation for potential animal-welfare violations after staff complaints about rushed animal testing. Ana Kasparian discusses on The Young Turks. Watch TYT LIVE on weekdays 6–8 pm ET. http://youtube.com/theyoungturks/live.

“Elon Musk’s Neuralink, a medical device company, is under federal investigation for potential animal-welfare violations amid internal staff complaints that its animal testing is being rushed, causing needless suffering and deaths, according to documents reviewed by Reuters and sources familiar with the investigation and company operations.

Continue reading “Neuralink NIGHTMARE: Elon’s Brain Chip Trials Are A Total Horror Show” »

If you’re expecting monoclonal antibody treatments to save you from getting more severe outcomes like death should you get Covid-19, it may be time to rethink that strategy. A letter published in The Lancet Infectious Diseases journal on November 18 detailed how many of the currently spreading Omicron subvariants, namely the BA.4.6, BA.2.75.2, and BJ.1 ones, appear to be resistant to most available monoclonal antibody treatments. And the BQ.1.1 Omicron subvariant, which has become one of the two dominant versions of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the U.S., seems resistant to all of the available monoclonal antibody treatments. Yes, all of them, as in every single one.

BQ certainly doesn’t stand for “be quiet,” as the BQ.1.1 subvariant is now causing a commotion, being responsible for an estimated 24.2% of all new reported Covid-19 cases over the past week while the not-too-different BQ.1 subvariant has been the culprit behind 25.5% of them, according to the Centers for Disease Control and Prevention (CDC). If you do the math, that means that these two Omicron subvariants are now comprising over half of all reported Covid-19 cases, meaning that they have overtaken the BA.5 as the “alpha-dog” of SARS-CoV-2 versions. Therefore, you can probably no longer rely on any type of monoclonal antibody should you get Covid-19. That’s certainly bad news for anyone not able to get enough protection from Covid-19 vaccination such as those who have very weak immune systems.

You know that 1997 Backstreet Boys song that goes “everybody, yeah?” Well, looks like the latest 2022 Covid-19 coronavirus Omicron subvariants have been going, “antibody, no-oh.” So much for the argument that other Covid-19 precautions are not needed because monoclonal antibodies are available. Even back in 2020 and 2021 when monoclonal antibody treatments seemed to work against the then-circulating previous versions of the virus, such an argument held water about as well as a Brillo pad thong since relying on any single Covid-19 precaution or treatment has always been a foolhardy approach. Doing so was akin to telling someone, “since you have underwear on, why do you need pants or a skirt or a kilt?” Ever since the start of the pandemic, real pandemic experts have continued to advocate for more of a “Swiss cheese” approach that entails always layering on different Covid-19 interventions simultaneously because each single intervention has its holes.

😗

BOSTON — Scientists at Dana-Farber Cancer Institute have developed a drug that potently neutralizes SARS-CoV-2, the COVID-19 coronavirus, and is equally effective against the Omicron variant and every other tested variant. The drug is designed in such a way that natural selection to maintain infectiousness of the virus should also maintain the drug’s activity against future variants.

The investigational drug, described in a report published today in Science Advances, is not an antibody, but a related molecule known as an ACE2 receptor decoy. Unlike antibodies, the ACE2 decoy is far more difficult for the SARS-CoV-2 virus to evade because mutations in the virus that would enable it to avoid the drug would also reduce the virus’s ability to infect cells. The Dana-Farber scientists found a way to make this type of drug neutralize coronaviruses more potently in animals infected with COVID-19 and to make it safe to give to patients.

Continue reading “New receptor ‘decoy’ drug neutralizes COVID-19 virus and its variants” »

A recent study from Tokyo Medical and Dental University found that melatonin and two of its metabolites help memories stick around in the brain and can shield mice, and potentially people, from cognitive decline. One of the easiest ways to test memory in mice is to rely on their natural tendency to examine unfamiliar objects.

Summary: Researchers have identified a protein that could be leveraged to help microglia in the brain stave off Alzheimer’s and other neurodegenerative diseases.

Source: The Conversation.

Many neurodegenerative diseases, or conditions that result from the loss of function or death of brain cells, remain largely untreatable. Most available treatments target just one of the multiple processes that can lead to neurodegeneration, which may not be effective in completely addressing disease symptoms or progress, if at all.

The drug, midazolam, is often used before surgery to make a patient feel more relaxed. According to a new study, it is associated with an increased risk of heart damage when surgeries are performed at night.

According to a study conducted by researchers at the University of Colorado Anschutz Medical Campus, a popular drug that makes patients sleepy and less anxious before surgery is associated with an increased risk of heart damage when surgeries are performed at night.

The results provide further proof that a drug’s effectiveness might vary depending on the time it is administered.

It has been described as “bringing your army right to the enemy.”

There’s a promising new therapy that makes the immune system kill bone marrow cancer cells. It has thus far been successful in as many as 73 percent of patients in two clinical trials, according to a report released by researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.

The novel therapy, called talquetamab, binds to both T cells and multiple myeloma cells and directs the T cells to exterminate multiple myeloma cells. It has been described as “bringing your army right to the enemy.”

Continue reading “‘New lease on life’: Bone marrow cancer therapy successful in 73% of patients” »

More than three years ago, this editor sat down with Sam Altman for a small event in San Francisco soon after he’d left his role as the president of Y Combinator to become CEO of the AI company he co-founded in 2015 with Elon Musk and others, OpenAI.

At the time, Altman described OpenAI’s potential in language that sounded outlandish to some. Altman said, for example, that the opportunity with artificial general intelligence — machine intelligence that can solve problems as well as a human — is so great that if OpenAI managed to crack it, the outfit could “maybe capture the light cone of all future value in the universe.” He said that the company was “going to have to not release research” because it was so powerful. Asked if OpenAI was guilty of fear-mongering — Musk has repeatedly called all organizations developing AI to be regulated — Altman talked about the dangers of not thinking about “societal consequences” when “you’re building something on an exponential curve.”

The audience laughed at various points of the conversation, not certain how seriously to take Altman. No one is laughing now, however. While machines are not yet as intelligent as people, the tech that OpenAI has since released is taking many aback (including Musk), with some critics fearful that it could be our undoing, especially with more sophisticated tech reportedly coming soon.

Microsoft today announced that it acquired Lumenisity, a U.K.-based startup developing “hollow core fiber (HCF)” technologies primarily for data centers and ISPs. Microsoft says that the purchase, the terms of which weren’t disclosed, will “expand [its] ability to further optimize its global cloud infrastructure” and “serve Microsoft’s cloud platform and services customers with strict latency and security requirements.”

HCF cables fundamentally combine optical fiber and coaxial cable. They’ve been around since the ’90s, but what Lumenisity brings to the table is a proprietary design with an air-filled center channel surrounded by a ring of glass tubes. The idea is that light can travel faster through air than glass; in a trial with Comcast in April, a single strand of Lumenisity HCF was reportedly able to deliver traffic rates ranging from 10 Gbps to 400 Gbps.

“HCF can provide benefits across a broad range of industries including healthcare, financial services, manufacturing, retail and government,” Girish Bablani, CVP of Microsoft’s Azure Core business, wrote in a blog post. “For the public sector, HCF could provide enhanced security and intrusion detection for federal and local governments across the globe. In healthcare, because HCF can accommodate the size and volume of large data sets, it could help accelerate medical image retrieval, facilitating providers’ ability to ingest, persist and share medical imaging data in the cloud. And with the rise of the digital economy, HCF could help international financial institutions seeking fast, secure transactions across a broad geographic region.”